Hypertension: Covidien launches OneShot renal denervation sales in global markets

January 16, 2013 by MassDevice staff

Medical device maker launches commercial sales of its OneShot renal denervation system in Europe, Middle East, Africa, Asia and Latin America.

Covidien logo

Medical device maker Covidien (NYSE:COV) this week announced commercial launch of its OneShot renal denervation system in markets around the world, bringing the company up to speed with some of its renal denervation rivals.

Over the next few months Covidien will roll out the device in markets in Europe, the Middle East, Africa, Asia and Latin America, according to a press release. No renal denervation system has yet been approved for sale in the U.S.

Sign up to get our free newsletters delivered right to your inbox.

Mansfield, Mass.-based Covidien faces some stiff competition in the renal denervation market, where Medtronic's (NYSE:MDT) Symplicity system, gained through the January 2011 acquisition of Ardian, already has a head start. Medtronic is also the closest winning to FDA approval for renal denervation, with U.S. clinical trials approved in the summer of 2011.